A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer

Epstein-Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the sa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2014-10, Vol.20 (19), p.5009-5022
Hauptverfasser:	Taylor, Graham S, Jia, Hui, Harrington, Kevin, Lee, Lip Wai, Turner, James, Ladell, Kristin, Price, David A, Tanday, Manjit, Matthews, Jen, Roberts, Claudia, Edwards, Ceri, McGuigan, Lesley, Hartley, Andrew, Wilson, Steve, Hui, Edwin P, Chan, Anthony T C, Rickinson, Alan B, Steven, Neil M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Combined Modality Therapy Epitopes, T-Lymphocyte - immunology Epstein-Barr Virus Infections - complications Epstein-Barr Virus Infections - virology Epstein-Barr Virus Nuclear Antigens - genetics Epstein-Barr Virus Nuclear Antigens - immunology Female Herpesvirus 4, Human - genetics Herpesvirus 4, Human - immunology Humans Immunophenotyping Lymphocyte Count Male Middle Aged Neoplasm Staging Neoplasms - diagnosis Neoplasms - etiology Neoplasms - prevention & control Neoplasms - therapy T-Cell Antigen Receptor Specificity T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism Treatment Outcome Vaccination Vaccinia virus - genetics Vaccinia virus - immunology Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!